Name: Q&A with Verici Dx CEO, Sara Barrington
Uploaded: 2022-09-07T06:15:36.290790+00:00
Duration: 1702 s
Channel: Vox Markets
Description: Positive trial results of the company’s 2 lead tests Tuteva (start) and Clarava (08:10). Broader validation of its innovative RNA technology platform. 13:05 Theoretical size of the addressable market. 16:55 Next steps for 3rd Protega diagnostic. 19:55 Significance of Illumina collaboration. 20;55 Cash runway ahead. 25:15 Future newsflow. 26:45

Vox Markets

Positive trial results of the company’s 2 lead tests Tuteva (start) and Clarava (08:10).
Broader validation of its innovative RNA technology platform. 13:05
Theoretical size of the addressable market. 16:55
Next steps for 3rd Protega diagnostic. 19:55
Significance of Illumina collaboration. 20;55
Cash runway ahead. 25:15
Future newsflow. 26:45

Positive trial results of the company’s 2 lead tests Tuteva (start) and Clarava (08:10). Broader validation of its innovative RNA technology platform. 13:05 Theoretical size of the addressable market. 16:55 Next steps for 3rd Protega diagnostic. 19:55 Significance of Illumina collaboration. 20;55 Cash runway ahead. 25:15 Future newsflow. 26:45

Positive trial results of the company’s 2 lead tests Tuteva (start) and Clarava

Broader validation of its innovative RNA technology platform

Theoretical size of the addressable market

Next steps for 3rd Protega diagnostic

Significance of Illumina collaboration

Cash runway ahead

Future newsflow

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/004/591/004591/video_FzTFBU9.mp4